Results 51 to 60 of about 8,420 (193)

The biodistribution and clearance of AlbudAb, a novel biopharmaceutical medicine platform, assessed via PET imaging in humans

EJNMMI Research, 2019
Conjugation or fusion to AlbudAbs™ (albumin-binding domain antibodies) is a novel approach to extend the half-life and alter the tissue distribution of biological and small molecule therapeutics.
Kevin S. Thorneloe, Armin Sepp, Sean Zhang, Laura Galinanes-Garcia, Paul Galette, Wasfi Al-Azzam, Danielle J. Vugts, Guus van Dongen, Phillip Elsinga, Johan Wiegers, Andor W. J. M. Glaudemans, Veena Vincent, Jessica Renaux, Matt Szapacs, Mary Birchler, Matthew Cleveland, Mats Bergstrom, Marie Davies   +17 more
doaj   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Target manufacturing by Spark Plasma Sintering for efficient 89Zr production

Nuclear Medicine and Biology, 2022
Zirconium-89 (89Zr) is an emerging radionuclide for positron emission tomography (PET), with nuclear properties suitable for imaging slow biological processes in cellular targets. The 89Y(p,n)89Zr nuclear reaction is commonly exploited as the main production route with medical cyclotrons accelerating low-energy (< 20 MeV) and low-current (< 100 μA ...
Cisternino, S, Cazzola, E, Skliarova, H, Amico, J, Malachini, M, Gorgoni, G, Anselmi-Tamburini, U, Esposito, J   +7 more
openaire   +3 more sources

89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors [PDF]

, 2012
The human epidermal growth factor receptor 2 (HER2/neu) is overexpressed in 20-30% of breast cancers and is associated with tumor growth, angiogenesis, and development of distant metastases.
Chang, Albert J., DeSilva, Ravindra, Jain, Sandeep, Lapi, Suzanne, Lears, Kimberley, Rogers, Buck   +5 more
core   +3 more sources

Molecular theranostics: principles, challenges and controversies

Journal of Medical Radiation Sciences, Volume 72, Issue 1, Page 156-164, March 2025.
Molecular theranostics offers a powerful tool to drive precision medicine in nuclear oncology. While theranostics is not a new principle in nuclear medicine, recent advances in instrumentation and radiopharmacy have driven a reinvigoration and a broader suite of applications.
Geoffrey Currie
wiley   +1 more source

How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans

EJNMMI Physics
Background PET scans using zirconium-89 labelled monoclonal antibodies (89Zr-mAbs), known as 89Zr-immuno-PET, are made to measure uptake in tumour and organ tissue. Uptake is related to the supply of 89Zr-mAbs in the blood.
Jessica E. Wijngaarden, Amina Ahbari, Johanna E. E. Pouw, Henri N. J. M. Greuter, Idris Bahce, Gerben J. C. Zwezerijnen, Daniëlle J. Vugts, Guus A. M. S. van Dongen, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt, Marc C. Huisman   +10 more
doaj   +1 more source

Boron‐10 carriers and their applications in boron neutron capture therapy

Precision Radiation Oncology, EarlyView.
Summary of different types of boron drugs. Abstract Boron neutron capture therapy (BNCT) has emerged as a promising therapeutic modality in cancer treatment, demonstrating the ability to selectively eliminate cancer cells through the 10B(n,α)7Li nuclear reaction with minimal side effects on normal tissues.
Dachao Tang, Mengqi Shi, Zhichen Mao, Weiya Chen, Xiaoling Li, Xiao Yan Zhao, Zhigang Liu, Xiao Xu   +7 more
wiley   +1 more source

The Research Progress of Monoclonal Antibody Labeled with 89Zr

Journal of Isotopes
Zirconium-89 (89Zr) is a metallic positron-emitting radionuclide. The relatively long half-life and moderate energy making 89Zr especially suitable for the labeling of large biomolecules such as antibodies for radioimmuno-PET (positron emission ...
Zhanxiong XIAO, Fei DUAN, Hongyu LI
doaj   +1 more source

ImmunoPET: IMaging of cancer imMUNOtherapy targets with positron Emission Tomography: a phase 0/1 study characterising PD-L1 with 89Zr-durvalumab (MEDI4736) PET/CT in stage III NSCLC patients receiving chemoradiation study protocol

BMJ Open, 2022
Background ImmunoPET is a multicentre, single arm, phase 0–1 study that aims to establish if 89Zr-durvalumab PET/CT can be used to interrogate the expression of PD-L1 in larger, multicentre clinical trials.Methods The phase 0 study recruited 5 PD-L1 ...
Christian Wichmann, Sagun Parakh, Gerard G Hanna, Thomas John, Jason Callahan, Benjamin Blyth, Michael MacManus, Daniel Steinfort, Andrew M Scott, Lisa Devereux, Fiona Hegi-Johnson, Stacey E Rudd, Tim Akhurst, Peter Roselt, Jenny Trinh, Paul S Donnelly, Rod Hicks, Stephen Fox, Kate Burbury   +18 more
doaj   +1 more source

Excitation functions for (p,x) reactions of niobium in the energy range of E$_{\text{p}}$ = 40-90 MeV [PDF]

, 2018
A stack of thin Nb foils was irradiated with the 100 MeV proton beam at Los Alamos National Laboratory's Isotope Production Facility, to investigate the $^{93}$Nb(p,4n)$^{90}$Mo nuclear reaction as a monitor for intermediate energy proton experiments and
Bernstein, Lee A., Birnbaum, Eva R., Engle, Jonathan W., Graves, Stephen A., Kawano, Toshihiko, Lewis, Amanda M., Nortier, Francois M., Voyles, Andrew S.   +7 more
core   +2 more sources